文献速递临床试验与 GCP真实世界研究与卫生经济

高血压控制的经济激励:原理与研究设计

Financial incentives for hypertension control: rationale and study design.
PubMed 文献 · Trials · 2020-02-03

本研究为多中心、随机对照试验,在中国辽宁和山西六城市纳入400例高血压患者,1:1区组随机分为干预组(移动设备互动管理加经济激励)和对照组(仅移动设备互动管理),主要结局为12个月收缩压净变化,旨在检验经济激励能否改善中国高血压患者的血压控制。

要点

  • 经济激励基于行为经济学概念,附加于移动设备互动管理之上
  • 主要结局为12个月收缩压较基线的净变化
  • 试验采用区组随机、1:1分组,血压测量与统计人员设盲

核心结论

  • 该试验将确定经济激励能否改善中国高血压患者的血压控制,并为控制高血压及伴随心血管疾病提供必要数据。

研究设计与样本

  • 多中心、随机对照试验,两平行组设计,在中国辽宁和山西六城市纳入400例高血压患者。
  • 采用区组随机按1:1比例分为干预组和对照组。
  • 对照组接受移动设备互动管理(含患者教育与沟通),干预组在此基础上附加经济激励,条件为达成降压目标或高血压控制。
  • 因干预的行为学性质无法对分组设盲,但血压测量和统计人员对临床分组设盲。

主要发现

  • 原文未报告结果数据。

关键数值与推荐

  • 主要结局为干预组与对照组之间12个月收缩压(SBP)较基线的净变化。
  • 次要结局包括舒张压(DBP)净变化、血压控制、用药依从性和生活方式变化以及成本效果。

临床怎么用

  • 若试验证实有效,经济激励可作为一种行为经济学干预策略用于改善中国高血压患者的治疗依从性和血压控制。

局限性

  • 因干预的行为学性质,无法对分组设盲。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Even though the effectiveness of lifestyle modifications and antihypertensive pharmaceutical treatment for the prevention of hypertension and its complications have been demonstrated in randomized controlled trials, the benefits of adhering to these treatments have not been popularized among the general public. Studies suggest that incentive approaches based on behavioral economic concepts can improve patients' adherence to treatment. Therefore, we aimed to test whether financial incentives will reduce the blood pressure (BP) of hypertensive patients in China. METHODS/DESIGN: This is a multicenter, randomized controlled trial with two parallel arms. A total of 400 participants from six cities in the Liaoning and Shanxi provinces of China are block-randomized into intervention and control group with a 1:1 ratio. Patients in the control group will receive interactive management of mobile devices, including patient education and communication. Patients in the intervention group will receive financial incentives in addition to interactive management of mobile devices, conditional on them achieving their antihypertensive goals or hypertension control. Masking the arm allocation will be precluded by the behavioral nature of the intervention and investigators of BP measurement and statistics are masked to clinic assignment. The primary outcome is net change in systolic BP (SBP) from baseline to month 12 between the intervention and control groups. The secondary outcomes are net change in diastolic BP (DBP), BP control, change in medication adherence and lifestyle, and cost-effectiveness. DISCUSSION: This trial will determine whether financial incentives will improve hypertension control and generate necessary data for controlling hypertension and concomitant cardiovascular diseases among hypertensive patients in China. TRIAL REGISTRATION: ISRCTN13467677. Registered on 16 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zheng L, Wang Y, Liu S, et al. Financial incentives for hypertension control: rationale and study design. Trials. 2020. PMID: 32014046. doi:10.1186/s13063-020-4051-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。